Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 2,950 $ 3,907
General and administrative 1,208 1,204
Total operating expenses 4,158 5,111
Loss from operations (4,158) (5,111)
Other income (expense):    
Interest income (expense), net 220
Foreign exchange loss (18) (78)
Total other income (expense), net 202 (78)
Net loss $ (3,956) $ (5,189)
Net loss per common share, basic $ (0.39) $ (0.64)
Net loss per common share, diluted $ (0.39) $ (0.64)
Weighted average number of common shares, basic 10,174 8,143
Weighted average number of common shares, diluted 10,174 8,143